Flu Testing Under New FDA Guidelines

Unless otherwise noted, P.A.C.E.™ accreditation will expire six months after the live webinar.

In this P.A.C.E.-accredited Fisher Healthcare™ webinar, Gregory J. Berry, PhD, D(ABMM), will discuss diagnostic tests that meet the FDA’s requirements and what can be learned from the most recent flu season.

The FDA reclassification of antigen-based influenza detection tests became effective on January 12, 2018. Although many providers have switched to molecular or reader technology, others continue to use assays that do not meet the reclassification requirements.

Learning Objectives

This webinar will help you:

• Summarize the FDA reclassification of antigen-based rapid influenza detection tests
• Describe available diagnostic testing options and the differences in performance
• Discuss the lessons learned from the 2017/18 influenza season in preparation for future seasons

Watch On Demand      Download Slides

This webinar is produced by Whitehat Communications, a provider of continuing education programs in clinical laboratory sciences that has been approved by the ASCLS P.A.C.E. Program. One P.A.C.E. credit hour will be provided for this complimentary, basic-level program.

Gregory J. Berry, PhD, D(ABMM)

Dr. Berry is currently an Assistant Professor of Pathology and Laboratory Medicine at Hofstra Northwell School of Medicine and an Assistant Director of Infectious Disease Diagnostics at Northwell Laboratories in New York. He is also a Diplomate of the American Board of Medical Microbiology.